2|0|Public
50|$|<b>Atrimustine</b> (INN) (developmental {{code name}} KM-2210), {{also known as}} bestrabucil or busramustine, is a {{nitrogen}} mustard alkylating antineoplastic drug that was under development in Japan by Kureha Chemicals (now Kureha Corporation) {{for the treatment of}} breast cancer and non-Hodgkin's lymphoma {{as well as for the}} prevention of graft-versus-host disease in bone marrow transplant recipients.http://webcache.googleusercontent.com/search?q=cache:aYPjqAoRa84J:adisinsight.springer.com/drugs/800000756+&cd=9&hl=en&ct=clnk&gl=us It is the benzoate ester of an ester conjugate of estradiol and chlorambucil, which results in targeted/site-directed DNA alkylating activity toward estrogen receptor-positive tissues such as breast and bone. It reached preregistration for the treatment of cancer but was ultimately discontinued.http://webcache.googleusercontent.com/search?q=cache:aYPjqAoRa84J:adisinsight.springer.com/drugs/800000756+&cd=9&hl=en&ct=clnk&gl=us Estrogenic side effects of <b>atrimustine</b> in clinical trials included vaginal bleeding and gynecomastia.http://webcache.googleusercontent.com/search?q=cache:aYPjqAoRa84J:adisinsight.springer.com/drugs/800000756+&cd=9&hl=en&ct=clnk&gl=us The drug was first patented in 1980.|$|E
50|$|Estramustine {{phosphate}} is an estrane steroid and an estrogen ester. It is {{a derivative}} and diester of estradiol with a nitrogen mustard-carbamate ester moiety and a phosphate ester attached. Related although never-marketed drugs include alestramustine, <b>atrimustine,</b> cytestrol acetate, estradiol mustard, ICI-85966, and phenestrol.|$|E

